New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing
March 20, 2023Business Services
STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
March 20, 2023Business Services
Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
March 20, 2023Business Services
Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Sun Pharma settles at $75m in industry-wide price-fixing case
March 17, 2023Sales and Marketing
Sun Pharma has decided a settlement of $75m as part of a case surrounding various pharma companies fixing their prices. …
Sanofi to cut insulin prices by 78% starting January 2024
March 17, 2023Sales and Marketing
French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 …
FDA approves Novartis’ Tafinlar and Mekinist combination
March 17, 2023Medical Communications
The FDA has approved Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of BRAF V600E low-grade glioma …
CANbridge Pharmaceuticals reports positive long-term data for glioblastoma multiforme drug
March 17, 2023Medical Communications
Chinese biopharmaceutical company CANbridge Pharmaceuticals has announced positive long-term follow-up data from its clinical studies into a glioblastoma multiforme (GBM) …
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer
March 17, 2023Business Services
Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …
Newron to present at the 31st European Congress of Psychiatry
March 17, 2023Business Services
Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
March 16, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients …
Great Ormand Street Hospital enters commercial agreement with Leucid Bio
March 16, 2023Medical Communications
Leucid Bio and Great Ormand Street Hospital NHS Foundation Trust (GOSH) have entered a commercial agreement to manufacture Leucid’s lead …
The Association of the British Pharmaceutical Industry suspends Novo Nordisk for two years
March 16, 2023Sales and Marketing
The Association of the British Pharmaceutical Industry (ABPI) has suspended Danish pharmaceutical company Novo Nordisk after “serious breaches” of the …
Seamless Therapeutics launches with $12.5m in financing
March 16, 2023Research and Development
Seamless Therapeutics, a biotech focusing on the therapeutic potential of gene therapies, has announced it received $12.5m (€11.8m) in seed …
Bristol Myers Squibb works with SpaceX to study biomanufacturing in space
March 16, 2023Medical Communications
It was announced last week that the SpaceX Dragon spacecraft will make its journey to the International Space Station (ISS) …
PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS
March 16, 2023Business Services
BASILDON, UK, 16 MARCH 2023 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the …
Zolgensma®▼ (onasemnogene abeparvovec) receives NICE final draft guidance in presymptomatic babies up to 12 months with spinal muscular atrophy (SMA)
March 16, 2023Business Services
London, UK, 16th March 2023 – Novartis Gene Therapies has confirmed that the National Institute for Health and Care Excellence …
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
March 16, 2023Business Services
Boston, Massachusetts, March 16th, 2023 – Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, …
Cough medicines containing pholcodine withdrawn across UK
March 15, 2023Medical Communications
Some cough syrups being sold behind the counter at pharmacies are being withdrawn due to safety concerns surrounding potential allergies …
Novo Nordisk to cut insulin prices by up to 75% in 2024
March 15, 2023Sales and Marketing
Danish pharmaceutical company Novo Nordisk has announced that it will cut its prices for insulin products by up to 75%, …
FDA amends EUA of Pfizer-BioNTech COVID-19 vaccine for paediatric use
March 15, 2023Medical Communications
Yesterday, the FDA announced that it has amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech bivalent COVID-19 Vaccine. The …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
